Aitiologic is a company headquartered in Austria.
Aitiologic develops a multi-modal liquid biopsy platform (aitios®) that analyzes genomic, epigenomic, and fragmentomic signals from cell-free DNA in blood for tissue-resolved diagnostics. Its initial application is a first-trimester non-invasive prenatal and preeclampsia test for early risk stratification.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.